RME Presents...Personalizing Multiple Myeloma Treatment for Maximum Benefit
Jointly provided by
Support for this activity has been provided through educational grants from Bristol-Myers Squibb; Celgene; Onyx Pharmaceuticals, an Amgen subsidiary; and Takeda Oncology.
Release date: 10/23/2015
Expiration date: 10/23/2016
Estimated time to complete: 1 hour
Achieving optimal outcomes for patients with multiple myeloma requires identifying the disease as early as possible and determining the best combination of agents based on a careful assessment of the biologic and genetic features of each patient’s disease. For hematologist-oncologists, the challenge of successfully managing myeloma has risen significantly as the number of therapeutic options has increased.
Today we invite you to join us in the Multiple Myeloma Virtual Institute Auditorium, where we are presenting a series of evidence-based presentations on factors that are critical to the successful management of patients with multiple myeloma. The featured presentations are How Is Risk Assessment Useful? From Smoldering to Symptomatic Myeloma, Should We Strive for Deepest Remission Possible in All Patients?, Balancing Maximum Benefit With Quality of Life, Clinical Considerations for Treatment Selection in Relapsed/Refractory Disease, and Multiple Myeloma Treatment: A Look Forward. Also available is the Resource Library, which houses tools that can help you more effectively manage patients with multiple myeloma.
A. Keith Stewart, MBChB, MRCP, FRCPC, MBA—Program Chair
Michele Cavo, MD, PhD
Institute of Hematology and Medical Oncology “Seràgnoli“
Bologna University School of Medicine
S. Orsola University Hospital
Thomas G. Martin, III, MD
University of California, San Francisco Medical Center
San Francisco, California
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Ontario, Canada
Ravi Vij, MD
Washington University School of Medicine
St. Louis, Missouri
This activity has been designed to meet the educational needs of hematologist-oncologists and medical oncologists involved in the care of patients with multiple myeloma.
Upon completion of this activity, participants should be able to:
- Utilize the International Staging System (ISS), cytogenetics, fluorescence in situ hybridization (FISH), and gene expression profiling to define patient prognosis and risk stratification
- Select treatment combinations in the frontline setting based on risk and patient-specific characteristics
- Assess treatment response to induction therapy and determine which patients will benefit from consolidation and/or maintenance therapy
- Select an appropriate course of therapy for patients who have relapsed from or become refractory to initial treatment
- Anticipate and proactively manage disease- and treatment-related side effects and toxicities to maintain compliance with treatment at the dose and schedule that is optimal to achieve best response
- Distinguish between the various novel agents in clinical development based on their mechanisms of action, safety, and preliminary efficacy
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Penn State College of Medicine is committed to offering CME programs that promote improvements or quality in health care and are developed free of the control of commercial interests. Reasonable efforts have been taken to ensure that programs are balanced, independent, objective, scientific, and in compliance with regulatory requirements. Faculty, course directors, and planners have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Disclosure of a relationship is not intended to suggest or condone bias but is made to provide participants with information that might be of importance to their evaluation of this educational activity. Disclosures are as follows:
A. Keith Stewart, MBChB, MRCP, FRCPC, MBA, has disclosed the following relevant financial relationships:
Consultant/Advisor: Array Biopharma, Bristol-Myers Squibb, Celgene
Michele Cavo, MD, PhD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Bristol-Myers Squibb, Celgene, Janssen, Millennium, Onyx
Speakers Bureau: Celgene, Janssen
Thomas G. Martin, III, MD, has disclosed the following relevant financial relationships:
Speakers Bureau: Millennium
Donna E. Reece, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, Celgene, Janssen, Johnson & Johnson, Onyx
Research Grant: Bristol-Myers Squibb, Celgene, Janssen, Johnson & Johnson, Merck, Millennium, Novartis, Otsuka
Ravi Vij, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Bristol-Myers Squibb, Celgene, Lilly, Onyx
Research Grant: Celgene, Onyx
Speakers Bureau: Celgene, Millennium, Onyx
Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Lauren Showers, Project Manager, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, an Amgen subsidiary, or Takeda Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. To receive CME credit, participants must review all activity information (including the learning objectives, disclosure statements, and content) and complete the posttest and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5849-16-T.
- Apple iPad or iPad mini (iOS 7 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser: Google Chrome, Internet Explorer 9 or higher, Firefox 26 or higher, or Safari 5 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required